Improving Anti-PD-1/PD-L1 Therapy for Localized Bladder Cancer

Area of Science:

• Urology
• Oncology
• Immunotherapy

Background:

• High-risk non-muscle invasive bladder cancer (HR-NMIBC) outcomes are worsened by poor response to Bacillus-Calmette Guérin (BCG).
• Muscle-invasive bladder cancer (MIBC) treatment success is limited by lack of response to neoadjuvant chemotherapy and cisplatin ineligibility.
• Immune checkpoint inhibitors (ICI) demonstrate efficacy in metastatic bladder cancer, prompting investigation in earlier stages.

Purpose of the Study:

• To review the current challenges and opportunities of PD-1/PD-L1 inhibition in HR-NMIBC and MIBC.
• To identify areas for improvement in patient stratification, efficacy enhancement, and toxicity reduction for ICI therapy.

Main Methods:

• Literature review of PD-1/PD-L1 immune checkpoint inhibitors in bladder cancer treatment.
• Analysis of current treatment limitations and emerging therapeutic strategies.

Main Results:

• ICI therapy presents potential benefits for HR-NMIBC and MIBC patients.
• Significant challenges remain, including patient response variability, immune-related adverse events, and high treatment costs.
• Gaps exist in identifying predictive biomarkers for ICI response and optimizing combination therapies.

Conclusions:

• PD-1/PD-L1 inhibition offers a promising avenue for treating HR-NMIBC and MIBC.
• Development of predictive biomarkers and synergistic combination regimens is crucial to maximize ICI efficacy and minimize toxicity.
• Addressing these gaps will improve patient stratification and overall treatment outcomes.